Development Pipeline
Development pipeline (as of February 1, 2018)
Development Pipeline [
147KB]
147KB]Oncology
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| AF802/RG7853 (CH5424802/ RO5424802) |
Non-small cell lung cancer (NSCLC) [1st line] # |
Approved (17/11) US |
alectinib Alecensa® Oral |
In-house Alecensa® (Roche) |
ALK inhibitor |
| Approved (17/12) Europe |
|||||
| RG7446 (MPDL3280A) |
NSCLC [2nd line] | Approved (18/01) |
atezolizumab Tecentriq® Injection |
Roche Tecentriq® |
Engineered anti-PDL1 monoclonal antibody |
| NSCLC [1st line] # |
Phase III Multinational study |
||||
| NSCLC (adjuvant) # |
Phase III Multinational study |
||||
| Small cell lung cancer # |
Phase III Multinational study |
||||
| Urothelial carcinoma # |
Phase III Multinational study |
||||
| Muscle invasive urothelial carcinoma (adjuvant) # |
Phase III Multinational study |
||||
| Renal cell carcinoma # |
Phase III Multinational study |
||||
| Renal cell carcinoma (adjuvant) # |
Phase III Multinational study |
||||
| Breast cancer # |
Phase III Multinational study |
||||
| Ovarian cancer # |
Phase III Multinational study |
||||
| Prostate cancer # |
Phase III Multinational study |
||||
| GA101/RG7159 (RO5072759) |
Follicular lymphoma | Filed (17/08) |
obinutuzumab Injection |
Roche Gazyva®/ Gazyvaro® (EU) (Nippon Shinyaku) |
Glycoengineered type II anti-CD20 monoclonal antibody |
| RG1273 (RO4368451) |
Breast cancer (adjuvant) # |
Filed (17/10) |
pertuzumab Perjeta® Injection |
Roche Perjeta® |
HER2 dimerization inhibitory humanized monoclonal antibody |
| Gastric cancer # |
Development discontinued | ||||
| RG435 (RO4876646) |
Renal cell carcinoma # |
Phase III Multinational study |
bevacizumab Avastin® Injection |
Roche Avastin® |
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody |
| RG3502 (RO5304020) |
Breast cancer (adjuvant) # |
Phase III Multinational study |
trastuzumab emtansine Kadcyla® Injection |
Roche Kadcyla® |
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate |
| RG7440 (GDC-0068) |
Prostate cancer | Phase III Multinational study |
ipatasertib Oral |
Roche/Array BioPharma | AKT inhibitor |
| Breast cancer | Phase III Multinational study |
||||
| RG7596 (RO5541077) |
Diffuse large B-cell lymphoma (DLBCL) |
Phase III Multinational study |
polatuzumab vedotin Injection |
Roche | Anti-CD79b antibody-drug conjugate |
| GC33/RG7686 (GC33/ RO5137382) |
Hepatocellular carcinoma | Phase I Multinational study* |
codrituzumab Injection |
In-house (Roche) |
Anti-Glypican-3 humanized monoclonal antibody |
| CKI27 (CKI27) |
Solid tumors | Phase I | Oral |
In-house |
Raf and MEK dual inhibitor |
| Phase I Overseas |
|||||
| RG7604 (GDC-0032) |
Solid tumors | Phase I | taselisib Oral |
Roche | PI3K inhibitor |
| ERY974 (ERY974) |
Solid tumors | Phase I Overseas |
Injection |
In-house | Anti-Glypican-3/CD3 bispecific antibody |
| RG7421 (GDC-0973) |
Solid tumors | Phase I | cobimetinib Oral |
Roche/Exelixis Cotellic® |
MEK inhibitor |
* Multinational studies managed by Chugai
Bone and Joint Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| ED-71 (ED-71) |
Osteoporosis | Phase III China |
eldecalcitol Edirol® Oral |
In-house | Activated vitamin D3 agent |
| NRD101 (NRD101) |
Knee osteoarthritis /Shoulder periarthritis |
Phase III China |
purified sodium hyaluronate Suvenyl® Injection |
In-house | Sodium hyaluronate |
Renal Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| EOS789 (EOS789) |
Hyperphosphatemia | Phase I | Oral |
In-house | - |
| Phase I Overseas |
Autoimmune Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| MRA/RG1569 (RO4877533) |
Giant cell arteritis # |
Approved (17/09) Europe |
tocilizumab Actemra® Injection |
In-house Actemra®/ RoActemra® (EU) (Roche) |
Humanized anti-human IL-6 receptor monoclonal antibody |
| Takayasu arteritis / Giant cell arteritis # |
Approved (17/08) |
||||
| Systemic sclerosis # |
Phase III Multinational study |
||||
| SA237/RG6168 (SA237) |
Neuromyelitis optica (NMO) | Phase III Multinational study* |
satralizumab Injection |
In-house (Roche) |
Anti-IL-6 receptor recycling antibody |
| RG7845 (GDC-0853) |
Rheumatoid arthritis | Phase I | Oral |
Roche |
BTK inhibitor |
* Multinational studies managed by Chugai
Neurology
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG1450 (RO4909832) |
Alzheimer’s disease | Phase III Multinational study |
gantenerumab Injection |
Roche/MorphoSys | Anti-amyloid-beta human monoclonal antibody |
| RG7412 (RO5490245) |
Alzheimer’s disease | Phase III Multinational study |
crenezumab Injection |
Roche/AC Immune | Anti-amyloid-beta humanized monoclonal antibody |
| RG6206 (BMS-986089) |
Duchenne muscular dystrophy (DMD) | Phase II/III Multinational study |
Injection |
Roche/Bristol-Myers Squibb | Anti-myostatin adnectin |
| RG7916 (RO7034067) |
Spinal muscular atrophy (SMA) | Phase II Multinational study |
Oral |
Roche/PTC Therapeutics | SMN2 splicing modifier |
Others
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| ACE910/RG6013 (RO5534262) |
Hemophilia A (Inhibitor) |
Approved (17/11) US |
emicizumab Injection |
In-house Hemlibra (Roche) |
Anti-FIXa/FX bispecific antibody |
| Filed (17/06) Europe |
|||||
| Filed (17/07) Japan |
|||||
| Hemophilia A (Non-inhibitor) |
Phase III Multinational study |
||||
| RG3637 (RO5490255) |
Idiopathic pulmonary fibrosis | Phase II Multinational study |
lebrikizumab Injection |
Roche | Anti-IL-13 humanized monoclonal antibody |
| CIM331** (CIM331) |
Pruritus in dialysis patients | Phase II | nemolizumab Injection |
In-house |
Anti-IL-31 receptor A humanized monoclonal antibody |
| URC102 (URC102) |
Gout | Phase II Overseas |
Oral |
In-house/JW Pharmaceutical (JW Pharmaceutical) |
URAT1 inhibitor |
| SKY59/RG6107 (RO7112689) |
Paroxysmal nocturnal hemoglobinuria (PNH) |
Phase I/II Multinational study |
Injection |
In-house (Roche) |
Anti-C5 recycling antibody |
| PCO371 (PCO371) |
Hypoparathyroidism | Phase I Overseas |
Oral |
In-house | PTH1 receptor agonist |
| RG7716 (RO6867461) |
Wet age-related macular degeneration / diabetic macular edema | Phase I |
Injection |
Roche | Anti-VEFG/Ang2 bispecific antibody |
** Development for atopic dermatitis: Out-licensed to Galderma (Overseas) and Maruho (Japan)
In principle, completion of first dose is regarded as the start of clinical studies in each phase.
IFRS References
ESG References
To view PDF files,
you will need Adobe® Reader® which is available as a free download.